News, Publications & Presentations 

Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...

Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...

Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma Uxbridge, UK and Lisbon, Portugal – 3 August 2020 –...

Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...

Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections Uxbridge, UK – 9 July 2020 – Immodulon, the immuno-oncology company, is pleased to note that a...

The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...

Dr. Habita brings deep expertise in clinical drug development, as the Company continues to seek to progress its uniquely differentiated clinical programmes in immuno-oncology Uxbridge, UK – 14 April 2020 – Immodulon, the immuno-oncology company, announces the...

Claims cover methods of treating pancreatic cancer or melanoma with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies New patents expected to expire in 2034 Immodulon’s IMM-101 is currently in a phase II clinical trial in combination with...

Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...

Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...

Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is...

Professor Abila brings extensive experience in clinical drug development. Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect. Professor Abila has...

Biomarker Research for IMM-101 Utilizing the Biodesix Diagnostic Cortex™ Platform BOULDER, Colo. and UXBRIDGE, UK, July 25, 2019 – Biodesix Inc. and Immodulon Therapeutics Limited, the immune-oncology company, today announced that they have entered into a...

Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration...

Immodulon, the immuno-oncology company, today announces the appointment of Dr Michael Bowles, as Medical Director, with immediate effect. Dr Ruslan Croitoru has chosen to step down as Chief Medical Officer to pursue other interests. A search for a new CMO is underway....

Dr Kleen brings extensive experience in immunology and immune monitoring to help further advance the company’s lead, novel immuno-oncology product, IMM-101 Uxbridge, UK, 23 May 2019 – Immodulon, the immuno-oncology company, today announces the appointment of Thomas O....

Immodulon, the immuno-oncology company, is pleased to announce that Ruslan Croitoru (MD MSc (Oxon) MFPM) will be joining the Immodulon Core Management Team as the Chief Medical Officer. Ruslan is a cardiologist. He gained his medical degree in Moldova, where he...

Immodulon, the immuno-oncology company, is pleased to announce that Maikel Dijkstal will be joining the Immodulon Core Management Team as CMC Programme Manager with immediate effect. Based in The Netherlands, Maikel has spent much of his working career in...

Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26...

Immodulon, the immuno-oncology company, is pleased to announce that Dr Kevin Bilyard, who served as CEO of Immodulon from 2008 to 2016 and more recently been an advisor to the company's Board of Directors, has accepted a position on the Immodulon Board. His career...